Company intelligence / Profile preview

GenFlow AI

Ownership: Private
Development stage: Commercial

Overview

Genflow's lead program GF-1002, a centenarian SIRT6-based gene therapy, has shown promising preclinical results. A 12-month proof-of-concept clinical trial in aged dogs began in March 2025. Human trials for MASH are planned for later in 2025.

Therapeutic areas: OtherMetabolic Disorders
Modalities: Gene therapyBiologic
Industry: Biotech

Partnerships

Heureka Labs Inc. – partnership to use Heureka’s AI platform for accelerating drug discovery and optimizing gene therapiesCER Groupe – Master Service Agreement for R&D and preclinical services

Beyond the preview

Go deeper on GenFlow AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenFlow AI.

Explore the full profile